This is echoed in a clinical practice discussion on addressing overweight and obesity, which reviews trial-level weight loss of around 1520% in major Phase 3 trials with current GLP-1 and dual-agonist agents and improvements in sleep apnea, fatty liver disease, and cardiovascular risk markers
This is consistent with the knowledge that GLP-1, as well as glucagon, has shown to possess powerful anti-inflammatory properties in vivo , an area that hold with vast therapeutical potential (136, 230)
GIP was originally thought to promote weight gain based on early research
For detailed management strategies, see our side effects guide
Once opened, the pen can be kept at room temperature, away from direct heat or light, but only for a limited timeusually up to 28 days